Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial

This publication has 27 references indexed in Scilit:

• DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial
  PLOS ONE, 2013
• Proportion of Deaths and Clinical Features in Bundibugyo Ebola Virus Infection, Uganda
  Emerging Infectious Diseases, 2010
• Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species
  PLoS Pathogens, 2010
• A Phase 1/2 Study of a Multiclade HIV‐1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV‐Uninfected East Africans (RV 172)
  The Journal of Infectious Diseases, 2010
• Isolation of Genetically Diverse Marburg Viruses from Egyptian Fruit Bats
  PLoS Pathogens, 2009
• Studies of Reservoir Hosts for Marburg Virus
  Emerging Infectious Diseases, 2007
• Isolates of Zaire ebolavirus from wild apes reveal genetic lineage and recombinants
  Proceedings of the National Academy of Sciences, 2007
• Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 DNA Candidate Vaccine
  The Journal of Infectious Diseases, 2006
• A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial
  Clinical and Vaccine Immunology, 2006
• Immune Protection of Nonhuman Primates against Ebola Virus with Single Low-Dose Adenovirus Vectors Encoding Modified GPs
  PLoS Medicine, 2006